Sirtori

Cesare Sirtori

Milan, Italy

University of Milan

Prof. Sirtori, Board Certified in Cardiology, has been Professor of Chemotherapy at the University of Milano and Professor of Clinical Pharmacology in the same University. Dean of the Faculty of Pharmacy from 2006 to 2012 and President of the Italian Atherosclerosis Society (1995-2001). Is currently President of the Italian Society of Nutraceutics (SINut). Has been President of the XIV Atherosclerosis Symposium in Rome, 2006, with over 6,000 participants.

Prof. Cesare Sirtori developed a career of Clinical Pharmacologist, having obtained, after the Medical Degree at the University of Milano (1967), the title of Doctor of Philosophy in Pharmacology at the University of Kansas, USA (1972). After his return to Italy, in 1972 he started in Milano one of the first Centers for the Study of Metabolic Diseases with a high atherosclerosis risk. The Center for Dyslipidemias (previously Center E. Grossi Paoletti), located at the Niguarda Ca’ Granda Hospital in Milano, is one the world’s largest Lipid Clinics (over 10,000 patients currently followed) and a leading Center for clinical research in the field of hyperlipoproteinemias, and non invasive monitoring of vascular lesions.

Author of over 600 scientific publications, more than 360 of which on high standard clinical and biological journals, quoted in over 12,000 publications.

Prof. Sirtori has provided significant contributions to the field of clinical pharmacology: kinetics of antidiabetic biguanides and detection of the first P-450 polymorphism (now CYP2D6) with phenformin; kinetics and mechanism of action of numerous compounds (celiprolol, ribavirin, acipimox, etc.); activity of different oral contraceptives on the P-450 system, and of hypolipidemic agents on carotid intima-media thickness.

Sessions by Cesare Sirtori

Lipoprotein changes after HDL infusion: Do they translate into improved functionality?

Monday (25 May) 16:15 - 16:45

  • Type:
    Afternoon X-Change Sessions
  • Theme:
    HDL Functionality
  • Track:
    Dyslipidemia

Stay up to date, subscribe to the newsletter

Progression and prevention of atherosclerosis and a translation to relevance.